# Regeneron's (REGN) Dupixent, the approval of the oncology drug linvoseltamab, the anticipated approval of another on.

*business · news · 2026-04-09 · CNBC*

## Key points

- Regeneron's Dupixent reached $17.8 billion in 2025 sales and is now approved for eight indications.
- Regeneron's obesity drug aims to promote weight loss while sparing muscle, unlike current GLP-1s.
- Eylea's U.S. market share is nearly 60%, but Roche's Vabysmo may surpass it by 2027.
- Regeneron's FY2026 revenue is estimated at $15.7 billion, a 9.5% year-over-year increase despite Eylea headwinds.
- The June $700/$850 bull call spread offers a defined-risk way to participate in REGN's potential upside.

**Companies:** Regeneron
**Countries:** United States

[Read the full story on CNBC](https://www.cnbc.com/2026/04/09/use-options-to-profit-on-a-catalyst-rich-biotech-poised-to-resume-a-recovery.html)

---

Canonical: https://newsio.io/n/def689a3-6bfa-436d-826e-51472b992949/regenerons-regn-dupixent-the-approval-of-the-oncology-drug-linvoseltamab-the-ant
Summarized by Newsio from CNBC. https://newsio.io/how-it-works